This meta-analysis, which includes data from 78 studies, successfully highlights and quantifies the positive prognostic value for those achieving a pathological complete response versus those with residual disease following the prescription of neoadjuvant therapies for human epidermal growth factor receptor-2-positive breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.